Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
Top Cited Papers
Open Access
- 24 June 2020
- journal article
- letter
- Published by Elsevier BV in Journal of Infection
- Vol. 81 (4), 647-679
- https://doi.org/10.1016/j.jinf.2020.06.052
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Clinicopathologic and Immunohistochemical Findings from Autopsy of Patient with COVID-19, JapanEmerging Infectious Diseases, 2020
- Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patientsEMBO Molecular Medicine, 2020
- Effective treatment of severe COVID-19 patients with tocilizumabProceedings of the National Academy of Sciences of the United States of America, 2020
- Cytokine storm intervention in the early stages of COVID-19 pneumoniaCytokine & Growth Factor Reviews, 2020
- Baricitinib therapy in COVID-19: A pilot study on safety and clinical impactJournal of Infection, 2020
- Tocilizumab treatment in COVID‐19: A single center experienceJournal of Medical Virology, 2020
- COVID-19: combining antiviral and anti-inflammatory treatmentsThe Lancet Infectious Diseases, 2020
- Department of ErrorThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from diseaseRespirology, 2018